Biotech IPO Landslide

Whirly lollipop on orange background.

We are profiling some individual deals but the biotechnology activity in the IPO market right now is overwhelming. Some market observers are calling it a market top in the segment. As we write this 75% of the deals in active marketing are biotechnology or pharma companies.

We've posted up these nine roadshows to the archive and there is a link to each one after the company blurb.

Argos Therapeutics (ARGS) develops personalized immunotherapies for the treatment of cancer and infectious diseases. Argos employs a specialized white blood cell, called a dendritic cell, to activate an . . .

Want the rest of the article?

Please login or join us as a member to view our complete content!